Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICG Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors
NCT05645523Phase 1Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Oct 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of indocyanine green in solid tumor, sponsored by St. Jude Children's Research Hospital. Primary endpoints: Percentage of patients in whom Indocyanine Green (ICG)-guided sentinel lymph node (SLN) mapping was successful and Percentage of patients with grade 3 or higher adverse events related to ICG use at 24 hours. Started Oct 2023; status: recruiting.
02
Drugs
indocyanine green
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05645523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05645523.